key: cord-0784081-c4vdo4r0
authors: Guiomar, R.; Santos, A. J.; Melo, A.; Costa, I.; Matos, R.; Rodrigues, A. P.; Kislaya, I.; Silva, A. S.; Roque, C.; Silva, C.; Aguiar, J.; Graca, F.; Graca, A.; Machado, A.
title: High correlation between binding IgG (anti-RBD/S) and neutralizing antibodies against SARS-CoV-2 six months after vaccination
date: 2021-12-13
journal: nan
DOI: 10.1101/2021.12.10.21267607
sha: 27865dd79e343bc9ca171cffd3a52a576d009e9c
doc_id: 784081
cord_uid: c4vdo4r0

Vaccination is considered the most important measure to control the COVID-19 pandemic. Extensive fol-low-up studies with distinct vaccines and populations are able to promote robust and reliable data to better understand the effectiveness of this pharmacologic strategy. In this sense, we present data regarding binding and neutralizing antibodies throughout time, from vaccinated and previously infected (PI) health care work-ers (HCW) in Portugal. We analyzed serum samples of 132 HCW, vaccinated and with previous SARS-CoV-2 infection. Samples were collected before vaccination (baseline, M1), at second dose vaccine uptake (M2), and 25-70 days (M3) and 150-210 days (M4) after the second dose for vaccinated individuals. The IgG (anti-RBD/S) antibody geometric mean titer found on vaccinated HCW at M2 (814.7 AU/ml; 95% CI 649.8-1021.5) were sig-nificantly higher than those found on PI HCW at recruitment (M1) (252.6 AU/ml; 95% CI 108.7 - 587.1), and the neutralizing antibodies (nAb) were similar between these groups, 93.2 UI/ml (95% CI 73.2- 118.5) vs. 84.1 UI/ml (95% CI 40.4-155.9), respectively. We detected about 10-fold higher IgG (anti-RBD/S) antibodies titers in M3 when compared with M2, with a slightly but significant decrease in titers from 36 days after the second dose vaccine uptake. The increase of nAb titers were correlated with IgG (anti-RBD/S) antibodies titers, how-ever, contrasting to IgG (anti-RBD/S) antibodies titers, we did not detect a decrease in nAb titer from 36 days after a second vaccine dose uptake. At M4, was observed a decrease of 8-fold in binding IgG (anti-RBD/S) and nAb. No significant differences in antibody titers were observed by sex, age or chronic diseases. Our results suggest that IgG (anti-RBD/S) antibodies titers and nAb titers could be correlated, but ongoing follow up of the cohort, is required to better understand this correlation, and the duration of the immune response.

Vaccination is an important public health measure to control the Coronavirus Disease 2019 caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Substantial effort 41 has been taken worldwide to develop vaccines able to protect against COVID- 19 [1] . anisms were used in vaccines development, among them, the novel technology of mRNA-based vac-43 cines [2] , such as Comirnaty® and Spikevax® and the adenoviral vector vaccines as Vaxzevria®, and 44 COVID-19 Vaccine Janssen® which are being used in the vaccination program of Portugal, to date [3] . 45 In the actual pandemic context, given the record time from the research to the production and mass 46 application of vaccines, the follow-up of vaccinated people is essential to obtain data regarding anti-47 body response among different populations, under different epidemiological contexts [4] . In addition 48 to the vaccine-effectiveness estimates, studies on immunogenicity are important to monitor vaccine 49 performance. 50 The Spike protein (S) of SARS-CoV-2 is actually the target used in most vaccine development, since 51 the receptor-binding domain (RBD), in subunit S1 of this protein, is considered the main target to 52 binding and neutralizing antibodies [5] . Thus, it is expected that vaccinated people present anti-pro-53 tein S antibodies, while people with previous COVID-19 may present anti-protein S and anti-nucleo-54 protein antibodies [6] . 55 Previous studies demonstrated high seroconversion (up to 90%) in both vaccinated and infected peo-56 ple, although high heterogeneity among individuals was observed [7] [8] [9] , however, the duration of the 57 adaptive immune response is not well established to date. Some studies have demonstrated antibodies 58 persistence in previously infected individuals for, at least, 12 months after symptoms onset [7] , and at 59 least 6 months after the complete vaccination scheme in vaccinated individuals [10] . 60 The correlation between binding and neutralizing antibodies titers and protection is not clear in infec-61 tion by SARS-CoV-2, and a cut off to predict protection is not available. A meta-analysis study based 62 on 7 different COVID-19 vaccines had evidenced a correlation between binding and neutralizing an-63 tibodies with protection against symptomatic COVID-19, indicating the use of antibodies tests to cor-64 relate protection against disease, but no threshold was established [11] . 65 In order to clarify questions regarding heterogeneity of immune response among individuals, dura-66 tion of the adaptive immune response, correlation among biding and neutralizing antibodies and pro-67 tection, the future need of vaccines boosters, among others, it is essential to carry on studies based on 68 real-life observation of different populations and on different vaccines. This is particularly true for 69 serological response and vaccine effectiveness measured at same time. The answers to these questions 70 are an important key to delineate the next strategies to control the COVID-19 pandemic. 71 In Portugal, the vaccination program against COVID-19 started in December 27, 2020. As in the ma-72 jority of European countries, the National Directorate of Health and the Ministry of Health defined a 73 strategy that prioritized front-line Health Care Workers (HCW) for vaccination, since they are essen-74 tial to maintain the health care units operational during the pandemic, but also because they are at 75 higher risk of SARS-CoV-2 infection, and given the closed contact between these professionals and 76 patients with comorbidities, with increased possibility of virus transmission to patients with high risk 77 for severe disease [12] . The first vaccines to be available in Portugal were Comirnaty® followed by 78 Spikevax® (both vaccines recommended to ≥12 years); Vaxzevria® (first recommended to individuals 79 aged less than 65 years and then changed into individuals aged 60 or more years) and Vaccine Janssen® (recommended to women aged ≥50 years old or adults men) [3] . Following the na-81 tional vaccination guidelines, during the study period those people with previous infection were vac-82 cinated after 6 months from the laboratory diagnosis, with one dose of any vaccine [13] . 83 The National Institute of Health Dr. Ricardo Jorge (INSA) has approximately 500 HCW in its staff, into 84 which 81 were considered as front-line HCW to receive the vaccine against COVID-19 in the first phase 85 of the national vaccination program. 86 The INSA institutional vaccination campaign began on 12 January 2021. HCW (aged ≥18 years old) 96 were invited to participate and were assigned into either the vaccinated cohort or the non-vaccinated 97 cohort at the beginning of the follow-up period. Individuals were asked to participate via institutional 98 email by the occupational medical service. 99 At the baseline, all participants filled-in a recruitment questionnaire were risk factors, symptoms and 100 vaccination data were collected. In addition, all participants were followed on a weekly basis, by fill-101 in an online questionnaire on SARS-CoV-2 exposure and infection symptoms. Nasopharyngeal/oro-102 pharyngeal swab was collected for SARS-CoV-2 detection by RT-PCR tests when reported suspected 103 signs and symptoms of COVID- 19 The participants of our cohort study that did not received any dose of vaccine or that had not a previ-111 ous infection were excluded of this analysis. 

We considered as vaccinated, individuals with more than 14 days after complete vaccination (receiv-115 ing all doses recommended in the product characteristics); and as partially vaccinated, individuals 116 with 14 days after receiving the first dose and until 14 days after receiving the second dose (in case of 117 2 doses). Additionally, as "previous infection" an individual who reported a positive RT-PCR test to 118 SARS-CoV-2 or had a positive RT-PCR test to SARS-CoV-2 and/or had anti-SARS-CoV-2 antibodies in 119 a serum sample taken in the recruitment at Moment 1(M1), before vaccine uptake. 120 121 2.5. Serological tests 122 Blood samples (3-5mL) were collected through venipuncture at baseline (M1) for all participants (in-123 cluding previously infected individuals), 30 days after first dose vaccine uptake (M2), 30 days after 124 second dose (M3) and at 6 months follow up (M4). After a centrifugation at 2500rpm for 15min serum 125 was obtained and conserved refrigerated (2 -8ºC) for a maximum of 7 days before laboratorial analysis 126 to detection of IgG antibodies and then, were stored frozen (-20ºC) until the neutralizing antibodies 127 test was performed. The determination of SARS-CoV-2 specific antibodies was done by a chemiluminescence enzyme im-132 munoassay used for quantitative detection of Anti-receptor-binding domain (RBD) from spike protein 133 (S) antibodies (IgG anti-RBD/S) against SARS-CoV-2. Assays were performed in serum samples by the 134 SARS-CoV-2 IgG II Quant assay (Abbott Diagnostics, IL, USA). Sera samples were considered positive 135 when presented results >50 AU/mL. The tests were performed according to the manufacturer's in-136 structions. 137 The determination of IgG(anti-RBD/S) was performed at baseline, before first vaccine dose uptake 138 (M1), before second vaccine dose uptake (M2), 25 to 70 days after second vaccine dose or completion 139 . CC-BY-NC 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 13, 2021. The determination of neutralizing antibodies was performed at M2, M3 and M4 to vaccinated partici-144 pants and at M1 to participants that had previous infection, using the commercial Enzyme-Linked 145 Immunosorbent Assay (ELISA) kit TECO® SARS-CoV-2 Neutralization Antibody Assay (TECOmedi-146 cal AG, Sissach, Switzerland), in the fully automated ELISA System DYNEX DS2®(Chantilly, VA, 147 USA). The test has the principle of competitive binding, based on protein-protein interaction from the 148 virus spike (S) protein (receptor binding domain -RBD) and the host cell receptor protein (angiotensin-149 converting enzyme 2 -ACE2). The test was performed according to the manufacturer's instructions. 150 The interpretation of the results was performed by the DYNEX DS2® system, and the results in IU/mL 151 was obtained based on the optic density (OD) of each sample. The limit of interpretation of the equip-152 ment is in the interval between 5 IU/mL and 500 IU/mL. Those samples that presented a value >500 153 IU/mL to nAb were re-analyzed in dilutions of 5X or 10X, to obtain the most robust result possible to 154 perform the statistical correlation among binding and neutralizing antibodies. The cutoff to determine 155 the presence of neutralizing antibodies was stablished as >20 IU/mL. Demographic, social and health characteristics of vaccinated (including partially vaccinated) individ-159 uals at baseline are described as relative frequencies for categorical and means and standard devia-160 tions for numerical variables. 161 For vaccinated, partially vaccinated and individuals with previous infection of COVID-19 data on the 162 quantification of IgG (anti-RBD/S) and nAb antibody response activity was represented as an esti-163 mated geometric mean (GM) with 95% confidence interval (95% CI). The Wilcoxon's rank sum test 164 was applied to detect statistical differences for the IgG (anti-RBD/S) titers (GMT) at different moments. 165 Between the 1st dose (20-30 days after vaccination, M2) and 2nd vaccine dose or completion of vac-166 cination scheme (25-70 days after vaccination, M3), and between these two moments and 5 to 7 months 167 after vaccination (150 to 210 days after 2nd dose or 1st dose in one uptake vaccine scheme, M4). Given 168 the difference of elapsed time since completion of vaccination scheme and blood sample collection at 169 the M3, we also tested the differenced in GMT for two moments after vaccination scheme completion 170 (25-35 days vs. 36-70 days). Spearman's coefficient and p-value were calculated to evaluate the corre-171 lation between IgG (anti-RBD/S) and neutralizing response activity (nAb). A linear regression was 172 performed on log-transformed IgG (anti-RBD/S) titers at the M3 (25 to 70 days after 2nd vaccine dose) 173 and at the M4 (150 to 210 days after 2nd vaccine dose) to determine the association to sex, age groups 174 (20-39, 40-70 years) or chronic disease (at least one chronic disease/no disease) for vaccinated individ-175 uals. Statistical significance was defined as p < 0.05. The study complied with legal and ethical requirements. The study protocol was approved by the 181 National Institute of Health Doctor Ricardo Jorge Health Ethics Committee. All participants provided 182 written informed consent for collection of data regarding demographic, social, and health information, 183 blood samples and nasopharyngeal/oropharyngeal swabs. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 13, 2021. ;

Out of 212 workers that integrated the INSA cohort at 15 June 2021, 132 were included in this study: 189 114 from the vaccinated and partially vaccinated group and 18 individuals with previous infection: 190 with a RT-PCR positive test (n=14) or with a positive serological analysis with the detection of anti-191 bodies against SARS-CoV-2 in serum sample (n=4). These 4 individuals were therefore unaware of 192 having been expose to the SARS- From the vaccinated group, 84 were vaccinated against SARS-CoV-2, and 30 were partially vaccinated 194 (Table 1) . Vaccinated participants had mostly taken the Comirnaty® vaccine (96.4%), the others with 195 COVID-19 Vaccine Janssen® (2.4%) and the Vaxzevria® (1.2%). Of the partially vaccinated individu-196 als, 66.7% had taken the Comirnaty®, 20% the Vaxzevria® and 13.3% the Spikevax. In both groups, 197 the majority were women (81% and 90%, respectively), and the mean of ages was lower for the vac-198 cinated group (x=44 (23-67) versus x=57(46-69)). Within the vaccinated group, over 68% reported to 199 work in laboratory, whereas over 81% of the partially vaccinated group reported to work in services 200 that did not required interaction with the public. Regarding smoking habits, 11% of the fully vac-201 cinated individuals and 23% of the partially vaccinated reported to be smokers. Little less than half of 202 vaccinated (48.7%) and 68.4% of the partially vaccinated participants reported at least one chronic 203 disease. In both groups, over 70% of participants reported to have uptake the influenza vaccine in the 204 previous season. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 13, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 13, 2021. ; https://doi.org /10.1101 /10. /2021 Table 2 displays the GM for IgG (anti-RBD/S) titers for different groups and moments. The concentra-220 tion of IgG (anti-RBD/S) was significantly higher (GM= 814.7 AU/mL; CI: 649.8-1021.5) for the vac-221 cinated individuals at M2, when compared to the values observed at M1 for the individuals previously 222 infected (GM= 252.6 AU/mL; CI:108.7-587.1) (p<0.001). 223 For vaccinated participants, antibodies titers were significantly higher after the second vaccine dose, 224 with an increase of about 10-fold from M2 to M3 in the IgG (anti-RBD/S) antibodies titers 225 (GM=8803.8AU/mL, 95 % CI: 7529.5-10293.7) (p<0.0001). For the M3, serum samples were drawn at 226 several distinct times, comprising a broad range of days between sample collection and second dose 227 uptake. Vaccinated individuals whose blood samples were drawn between 25 and 35 days after the 228 second dose presented a higher GM of IgG (anti-RBD/S) concentration (GM=10773.0AU/mL, CI:8910.2-229 13025.3), compared to those whose sample collection took place after the 35 until 70 days 230 (6912.1AU/mL, CI:5447.3-8770.8) (p<0.05). Even though the concentration of IgG (anti-RBD/S) titers 231 decreased at M4 (GM= 1070.4 AU/mL; CI: 922.5-1241.9) and was significantly lower when compared 232 to the values observed at M3 (p<0.001). Antibody titers at M4 were still significantly higher than ob-233 served for the vaccinated individuals at M2, after the 1 st vaccine dose (p<0.05). Table 2 

[CI95%] (n)

[CI95%] (n)

(Vaccinated)

[CI95%] (n)

[CI95%] (n)

[CI95%] (n)

[CI95%] (n) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Linear regression was performed on log-transformed IgG (anti-RBD/S) titers at the M3 and M4 to de-239 termine the association to sex, age groups or chronic disease for vaccinated individuals (Table 3) . No 240 statistical differences (p>0.05) in the GM of IgG (anti-RBD/S) concentration were observed between 241 men or women, between individuals in the two age groups or between individuals without or with at 242 least one chronic disease at each of the observed moments. To explore the humoral immune response generated after SARS-CoV-2 infection, the neutralizing an-249 tibody response (nAb) was evaluated for individuals with previous infection at recruitment ( is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 13, 2021. ; https://doi.org /10.1101/2021.12.10.21267607 doi: medRxiv preprint

255 Table 4 [CI95%] (n)

(Vaccinated)

[CI95%] (n)

[CI95%] (n)

[CI95%] (n)

[CI95%] (n) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 13, 2021. ; https://doi.org /10.1101 /10. /2021 High statistically significant correlations were observed between IgG (anti-RBD/S) and nAb titers, at 271 all observational moments. After the first vaccine dose (M2) IgG (anti-RBD/S) titers correlated highly 272 with nAb titers (Spearman's ρ = 0.79, p<0.001). Similar higher correlations were observed at M3 273 (Spearman's ρ = 0.86, p<0.001), either 25 to 35 days (Spearman's ρ = 0. 81, p<0.001) or 36 to 70 days 274 after completion of vaccination scheme (Spearman's ρ = 0. 87, p<0.001). Finally, at M4, a significant 275 correlation, was observed between IgG (anti-RBD/S) and nAb titers (Spearman's ρ = 0.70, p<0.001). 276 277

In this work, we accessed the preliminary data regarding binding and neutralizing antibodies in 279 HCW from National Public Health Institute, Portugal, from the baseline, before first vaccine dose 280 uptake, until 150-210 days (5-7 months) after the second vaccine dose. We demonstrated that the first 281 vaccine dose elicited an immunological response although a second dose was essential to promote a 282 boost in binding and neutralizing antibodies SARS-CoV-2. IgG (anti-RBD/S) were highly correlated 283 with neutralizing antibodies, being higher in the first 70 days (10 weeks), keeping however a good 284 correlation after completion of the vaccination scheme. 285 The IgG (anti-RBD/S) titer was significantly higher in vaccinated individuals, after one or two vac-286 cine doses, compared with baseline values of individuals that had developed an immunity response 287 after a previous SARS-CoV-2 infection. The GM of IgG (anti-RBD/S), after one vaccine dose, from 288 vaccinated individuals was significantly higher (p<0.001) than GM found at recruitment for individ-289 uals that had a previous infection. This data is in accordance with the previously reported from a 290 cohort of HCW from an academic medical center in Southern California [14] and with the Portuguese 291 national serological survey performed in February-March 2020 [15] . However, we have to take in 292 consideration that the elapsed time between infection and the recruitment to this study had a great 293 variation among individuals. Due to the lower sample size between these groups, it is not possible 294 to perform a robust comparative analysis in the group of previous SARS-CoV-2 infection. 295 The marked increase of the IgG (anti-RBD/S) after the second dose, found in this study was compat-296 ible with the observed in previous studies [6, 8, 10, 14] , and in trials studies [16] . It is important to high-297 light that after the second dose we found a significant decrease for IgG (anti-RBD/S) between indi-298 viduals that had a serum analysis from 25 to 35 days and those that had a serum analysis from 36 to 299 70 days, after the second dose. This decrease was expected given that after the second dose there is 300 a high stimulation of immune system, with high production of antibodies, however it is not expected 301 that the IgG titers be kept at the maximum for a long time, and though a decreasing to basal titers of 302 memory is generally observed [17, 18] . This decrease was also found in other studies [10, 19] . In this 303 sense, is important to keep the follow up of the cohort studies in order to clear for how long the IgG 304 titers remains and to try to correlate this data with nAb, and to establish a cut off that could predict 305 protection against SARS-CoV-2 infection. Other studies in health care workers showed that the effi-306 cient immunological response to COVID-19 vaccines is associated with a reduction of new COVID-307 19 cases among those who received two doses of the vaccine, even when a surge of the B.1.1.7 variant 308 was noted in up to 80% of cases. The effective vaccination among health care workers provides a 309 safe environment, even in the presence of a high rate of SARS-CoV-2 infection in the community. 310 Although there is a good effectiveness for COVID-19 vaccines, is recognized a decrease in vaccine 311 effectiveness with time [20] . A study from England, found high levels of vaccine effectiveness against 312 symptomatic disease after two doses, even when a new variant Delta was circulating [21] . New 313 variants can also pose a challenge to COVID-19 vaccine effectiveness that expresses the perfusion 314 stabilized full spike glycoprotein (S) of the original SARS-CoV-2 isolate Wuhan-Hu-1, but recent 315 studies have already highlighted that variants of concern [22], Alpha (B.1.1.7 variant), Beta variant 316 first identified in South Africa (B.1.351 lineage), and Gamma variant first identified in Brazil (P.1 317 lineage) remained susceptible to Comirnaty® vaccine elicited serum neutralization, although at a 318 reduced level for the B.1.351 variant [23, 24] . For the Delta variant, predominant in Portugal since 319 mid-June 2021 [25] , studies on cross-reactivity of monoclonal antibodies to pre-existing SARS-CoV-320 2 strains, showed that vaccination of previously infected individuals is likely to be protective against 321 a large array of circulating viral strains, including the Delta variant. In the same way, two-dose reg-322 . CC-BY-NC 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 13, 2021. ;  imen generated high sera-neutralization levels against the Alpha, Beta and Delta variants in individ-323 uals sampled at week 8 to week 16 after vaccination [26] , being the levels of neutralizing antibodies 324 highly predictive of immune protection from symptomatic SARS-CoV-2 infection [27] . A study at 325 national level estimated high mRNA VE for the prevention of COVID-19-related hospitalizations 326 and deaths (in ≥ 65 years, full vaccinated) with any evidence of VE reduction in the 3 months after 327 the second dose uptake, during the period of Delta variant circulation [28] , consistent with the high 328 titers for binding and neutralizing antibodies detected after complete vaccination. 329 In opposite to other studies such as one performed in UK, where people older than 50 years old 330 presented a weaker serological response in relation to those younger than 50 years old [29] , in our 331 study we did not identify any difference between age, sex, or the presence of one or more chronic 332 diseases. This fact can be due to the limited sample size of our study, which do not allow a more 333 robust analysis. 334 Our study has some limitations, the cohort includes only active healthy workers, without severe 335 comorbidities, and all participants are under 70 years old, with over representation of the female 336 population. The occupational risk is reduced, although the majority of the participants manipulate 337 SARS-CoV-2 positive samples, strict guidelines to use individual protective equipment limit the oc-338 cupational risk exposure being reduced compared to medical personnel with close contact with pa-339 tients. The heterogeneity in the reference units to quantify the detected antibodies posed a difficulty 340 to compare our data with other studies. Few studies used the same units that we used in this study. 341 This point was already highlighted by Earle et al., [11] that suggested the use of the WHO Interna-342 tional Standard (NIBSC 20/136) to express neutralizing antibodies titers in IU/mL and binding anti-343 bodies titers in BAU/mL to be possible to compare data among different studies using serology as-344 says, in the context of COVID-19 pandemic. Given the importance to compare different vaccines 345 among different populations to help to design new strategies to battle the pandemic, this point is 346 crucial to a better comprehension of data obtained around the world. We didn´t explore the antibody 347 titers for variants of concern, and a decrease of antibody titers could be expected. The cellular im-348 munity and other immunological mechanisms weren´t explored during the study. 349 In our study, we found a high correlation between biding and neutralizing antibodies after the first 350 dose and similar results have been previously reported by other authors [30, 31] . It was reported that 351 nAb remain relatively stable for several months after infection, but there is a lack of information on 352 for how long time it persists [31] . The slower decrease in nAb after the second vaccine dose uptake, 353 could support a robust and long persistence of nAB after full vaccination [20, 31, 32] . A recent study 354 reported a good correlation between binding and neutralizing antibodies levels and protection 355 against symptomatic infection [33] . Although we observed a decrease in nAb titers levels about 6 356 months after vaccination, it was high far away from the minimum level reported by ciated with 80%VE against symptomatic infection, with majority Alpha variant (26 IU/mL for pseu-358 dovirus neutralization). In our study, we were not able to predict the loss of protection due to the 359 decrease of nAb at 5-7 months after full vaccination neither to confirm that the nAb levels found at 360 this moment are considered a robust immune response. In this sense, we recommend caution in the 361 interpretation of the decrease of the levels of biding and neutralizing antibodies, especially in face to 362 the new variants challenge. 363 The preliminary data obtained from our cohort study demonstrate the importance to keep the follow 364 up of the individuals in order to better understand the behavior of immune response to the COVID-365 19 vaccines, and to try to establish a threshold that could predicts protection against the SARS-CoV-366 2 infection. Serological studies precluding the waning of antibody levels with time must be inte-367 grated in the vaccine effectiveness studies to better clear questions about the duration of immune 368 protection and vaccine effectiveness. The data on waning immunity and vaccine effectiveness con-369 stitute important facts for health decision makers, to implement measures to reduced severe disease, 370 mortality and transmission that could comprises non-pharmaceutical measures and/or additional 371 booster vaccine doses. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted December 13, 2021. ;

Of COVID-19 Vaccine Effectiveness

COVID-19 vaccines: where we stand and challenges ahead

INFARMED INFARMED COVID-19 -VACINAS APROVADAS (quadro resumo)

Humoral immune 396 responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective 397 immunity

Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines

Antibody response to the bnt162b2 mrna covid-19 vaccine in subjects with prior sars-cov-2 infection

Persistence and baseline determinants of seropositivity 406 and reinfection rates in health care workers up to 12.5 months after COVID-19

Antibody 409 response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 410 infection

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-413 infected individuals

Antibody Persistence through 6 Months after the 415

Second Dose of mRNA-1273 Vaccine for Covid-19. new Engl

SARS-CoV-2 exposure, symptoms and seroprevalence in 421 healthcare workers in Sweden

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously 425 infected with SARS-CoV-2

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine 430

Interpreting Diagnostic Tests for SARS-CoV-2

Immune response to SARS-CoV-2 and mechanisms of immunopathological 435 changes in COVID-19. Allergy Eur

Human IgG and IgA 437 responses to COVID-19 mRNA vaccines

Effectiveness of mRNA Covid-19 Vaccine among

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

ECDC SARS-CoV-2 variants of concern as of 23

450 et al. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants

INSA) Diversidade genética do novo coronavírus 453 SARS-CoV-2 (COVID-19) em Portugal

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody 456 neutralization

Neutralizing antibody levels are highly predictive of 459 immune protection from symptomatic SARS-CoV-2 infection

adults : a cohort study based on data linkage of national health registries in Portugal

Effect of 467 previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine

Comparison of IgG and neutralizing antibody responses after one or 471 two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals

EClinicalMedicine 2021

Robust neutralizing antibodies to SARS-CoV-2 infection persist for 475 months

Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the 478 next 5 years

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

We would like to acknowledge all the participants from the staff of the National Institute 382 of Health for the availability to participate in the present study and to donate blood samples for the evaluation 383 of the humoral immunity response after vaccination. 384 We acknowledge the colleagues that contributed to the support of the present study: Paula